Home > News

 

 

ARCHIVE NEWS
Chiesi Announces Results of the Tanimilast Phase III PILASTER Clinical Study in Chronic Obstructive Pulmonary Disease (COPD)
23 September 2025
ISO 37001:2016 Certification: Chiesi Farmaceutici Starts the Extension Process of the Certification to the Affiliates of the Group
08 May 2025
LEED Certification: Sustainable Workspaces for People and the Planet
12 March 2025
In Memory of Dr. Paolo Chiesi: Visionary Leader and Innovator
05 March 2025
Embracing Sustainability and Inclusivity: Updated Code of Interdependence
24 February 2025
Chiesi Group Reaffirms Its EcoVadis Platinum Medal
13 December 2024
Chiesi Group’s near and long-term science-based emissions reduction targets have been validated by the SBTi
25 October 2024
Code of Interdependence Workshop: a great opportunity for collaboration
25 September 2024
Chiesi to Present Data at the American Thoracic Society Conference
17 May 2024
Empowering Diversity & Inclusion: Chiesi Affinity Networks
10 May 2024
© 2025 CHIESI Farmaceutici S.p.A.
VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE


follow us on: